Trials / Withdrawn
WithdrawnNCT04288765
Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Grupo Cooperativo de Hemopatías Malignas · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Carfilzomib in combination with lenalidomide, daratumumab and dexamethasone (KRDd) can induce profound clinical responses. The investigators want to observe the effectiveness of the quadruple therapy of carfilzomib, lenalidomide, daratumumab and dexamethasone on patients receiving 8 cycles of KRDd with autologous stem cell transplantation versus patients with 8 cycles of KRDd without autologous stem cell transplantation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Daratumumab Only Product in Parenteral Dose Form | Induction = 8 cycles Carfilzomib on Day 1st, 8th and 15th Lenalidomide: Day 1 to 21 Daratumumab: Cycles 1-2: weekly Cycles 3-4: every two weeks Cycles 5-8: every month Dexamethasone: 40 mg weekly |
Timeline
- Start date
- 2020-03-01
- Primary completion
- 2024-12-31
- Completion
- 2025-02-28
- First posted
- 2020-02-28
- Last updated
- 2021-07-09
Locations
1 site across 1 country: Mexico
Source: ClinicalTrials.gov record NCT04288765. Inclusion in this directory is not an endorsement.